Fadia S Youssef1, Mohamed L Ashour1,2, Sherif S Ebada1, Mansour Sobeh2, Hesham A El-Beshbishy3,4, Abdel Nasser Singab1, Michael Wink2. 1. Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. 2. Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany. 3. Medical Laboratory Sciences Department, Fakeeh College for Medical Sceinces, Jeddah, Saudi Arabia. 4. Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Abstract
OBJECTIVES: This study was designed to evaluate the antihyperglycaemic activity of the methanol leaf extract of Eremophila maculata (EMM) both in vitro and in vivo. METHODS: The antihyperglycaemic activity was assessed in vitro using differentiated 3T3-L1 adipocytes, whereas in-vivo effect was evaluated in streptozotocin-induced diabetic rats. Chemical profiling of EMM was done using LC-ESI-MS techniques. Molecular modelling experiments of the identified compounds were performed using C-Docker protocol. KEY FINDINGS: Eremophila maculata slightly enhanced cellular glucose uptake and utilization in vitro by 3.92% relative to the untreated control. A stronger in-vivo effect was observed for EMM and its dichloromethane fraction. A pronounced elevation in serum insulin by 88.89 and 66.67%, respectively, accompanied by an apparent decline in fasting blood glucose (FBG) level by 65.60 and 70.37% comparable to streptozotocin-induced diabetic rats was observed. This effect was stronger than that of the reference drug glibenclamide (GLB). Chemical profiling of EMM revealed that leucoseptoside A, verbascoside, syringaresinol-4-O-β-D-glucopyranoside, pinoresinol-4-O-β-D-glucopyranoside and pinoresinol-4-O-[6″-O-(E)-feruloyl]-β-D-glucopyranoside are the major compounds. Molecular modelling showed that martynoside, verbascoside and phillygenin exhibited the highest inhibition to human pancreatic α-amylase (HPA), maltase glucoamylase (MGAM) and aldose reductase (AR), respectively. CONCLUSION: Eremophila maculata offers an interesting relatively safer antihyperglycaemic candidate comparable to synthetic analogues.
OBJECTIVES: This study was designed to evaluate the antihyperglycaemic activity of the methanol leaf extract of Eremophila maculata (EMM) both in vitro and in vivo. METHODS: The antihyperglycaemic activity was assessed in vitro using differentiated 3T3-L1 adipocytes, whereas in-vivo effect was evaluated in streptozotocin-induced diabeticrats. Chemical profiling of EMM was done using LC-ESI-MS techniques. Molecular modelling experiments of the identified compounds were performed using C-Docker protocol. KEY FINDINGS:Eremophila maculata slightly enhanced cellular glucose uptake and utilization in vitro by 3.92% relative to the untreated control. A stronger in-vivo effect was observed for EMM and its dichloromethane fraction. A pronounced elevation in serum insulin by 88.89 and 66.67%, respectively, accompanied by an apparent decline in fasting blood glucose (FBG) level by 65.60 and 70.37% comparable to streptozotocin-induced diabeticrats was observed. This effect was stronger than that of the reference drug glibenclamide (GLB). Chemical profiling of EMM revealed that leucoseptoside A, verbascoside, syringaresinol-4-O-β-D-glucopyranoside, pinoresinol-4-O-β-D-glucopyranoside and pinoresinol-4-O-[6″-O-(E)-feruloyl]-β-D-glucopyranoside are the major compounds. Molecular modelling showed that martynoside, verbascoside and phillygenin exhibited the highest inhibition to human pancreatic α-amylase (HPA), maltase glucoamylase (MGAM) and aldose reductase (AR), respectively. CONCLUSION:Eremophila maculata offers an interesting relatively safer antihyperglycaemic candidate comparable to synthetic analogues.
Authors: Mansour Sobeh; Mona F Mahmoud; Ganna Petruk; Samar Rezq; Mohamed L Ashour; Fadia S Youssef; Assem M El-Shazly; Daria M Monti; Ashraf B Abdel-Naim; Michael Wink Journal: Front Pharmacol Date: 2018-06-05 Impact factor: 5.810
Authors: N'Goran M Kouamé; Camille Koffi; Kanga S N'Zoué; N'Guessan A R Yao; Brahima Doukouré; Mamadou Kamagaté Journal: Evid Based Complement Alternat Med Date: 2019-10-16 Impact factor: 2.629
Authors: Iriny M Ayoub; Michal Korinek; Mohamed El-Shazly; Bernhard Wetterauer; Hesham A El-Beshbishy; Tsong-Long Hwang; Bing-Hung Chen; Fang-Rong Chang; Michael Wink; Abdel Nasser B Singab; Fadia S Youssef Journal: Plants (Basel) Date: 2021-05-31